These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 23322588)
41. Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology. Inotai A; Pékli M; Jóna G; Nagy O; Remák E; Kaló Z BMC Health Serv Res; 2012 Sep; 12():332. PubMed ID: 22999574 [TBL] [Abstract][Full Text] [Related]
42. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
43. Ontario's formulary committee: how recommendations are made. PausJenssen AM; Singer PA; Detsky AS Pharmacoeconomics; 2003; 21(4):285-94. PubMed ID: 12600223 [TBL] [Abstract][Full Text] [Related]
44. The use of economic evaluations in NHS decision-making: a review and empirical investigation. Williams I; McIver S; Moore D; Bryan S Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906 [TBL] [Abstract][Full Text] [Related]
45. The impact of cancer drug wastage on economic evaluations. Truong J; Cheung MC; Mai H; Letargo J; Chambers A; Sabharwal M; Trudeau ME; Chan KKW Cancer; 2017 Sep; 123(18):3583-3590. PubMed ID: 28640362 [TBL] [Abstract][Full Text] [Related]
46. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations. Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323 [TBL] [Abstract][Full Text] [Related]
47. The Use of Economic Evidence to Inform Drug Pricing Decisions in Jordan. Hammad EA Value Health; 2016; 19(2):233-8. PubMed ID: 27021758 [TBL] [Abstract][Full Text] [Related]
48. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations. Niraula S; Nugent Z J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993 [No Abstract] [Full Text] [Related]
49. Role of economic evidence in coverage decision-making in South Korea. Bae EY; Kim HJ; Lee HJ; Jang J; Lee SM; Jung Y; Yoon N; Kim TK; Kim K; Yang BM PLoS One; 2018; 13(10):e0206121. PubMed ID: 30356251 [TBL] [Abstract][Full Text] [Related]
50. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L Value Health; 2010; 13(1):3-7. PubMed ID: 19874571 [TBL] [Abstract][Full Text] [Related]
51. Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013. Pauwels K; Huys I; De Nys K; Casteels M; Simoens S Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):859-68. PubMed ID: 25978862 [TBL] [Abstract][Full Text] [Related]
52. [Pharmacoeconomics and cost of cancer drugs]. Camps Herrero C; Caballero Díaz C; Blasco Cordellat A Farm Hosp; 2010 Mar; 34 Suppl 1():12-5. PubMed ID: 20920852 [TBL] [Abstract][Full Text] [Related]
53. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making? Anell A; Persson U Eur J Health Econ; 2005 Sep; 6(3):274-9. PubMed ID: 15968561 [TBL] [Abstract][Full Text] [Related]
54. Evolution of drug reimbursement in Canada: the Pan-Canadian Pharmaceutical Alliance for new drugs. Husereau D; Dempster W; Blanchard A; Chambers J Value Health; 2014 Dec; 17(8):888-94. PubMed ID: 25498784 [TBL] [Abstract][Full Text] [Related]
55. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies. Barbieri M; Hawkins N; Sculpher M Value Health; 2009; 12(2):193-201. PubMed ID: 18700865 [TBL] [Abstract][Full Text] [Related]
56. Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors. Linley WG; Hughes DA Pharmacoeconomics; 2012 Sep; 30(9):779-94. PubMed ID: 22676385 [TBL] [Abstract][Full Text] [Related]
57. How much is the life of a cancer patient worth? A pharmaco-economic perspective. Simoens S; Dooms M J Clin Pharm Ther; 2011 Jun; 36(3):249-56. PubMed ID: 21545607 [TBL] [Abstract][Full Text] [Related]
58. [Limitations of pharmacoeconomics from a clinical-pharmacological point of view]. Müller M Wien Med Wochenschr; 2006 Dec; 156(23-24):619-21. PubMed ID: 17211766 [TBL] [Abstract][Full Text] [Related]
59. Using economic evaluations to make formulary coverage decisions. So much for guidelines. Anis AH; Gagnon Y Pharmacoeconomics; 2000 Jul; 18(1):55-62. PubMed ID: 11010604 [TBL] [Abstract][Full Text] [Related]
60. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]